Background drugs and low maraviroc levels explain resistance in Motivate studies
1 February 2008. Related: Conference reports, Drug resistance.
Conference reports
38th World Conference on Lung Health of the Union Against TB and Lung Disease, December 2007, Cape Town
1 February 2008. Related: Conference reports.
Treatment outcomes in patients who received rifampicin with nevirapine or efavirenz
1 February 2008. Related: Conference reports, TB coinfection.
11th European AIDS conference (EACS), October 24-27 2007, Madrid
2 December 2007. Related: Conference reports.
New European guidelines launched (2007)
2 December 2007. Related: Conference reports, Guidelines.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Drug interaction studies presented at EACS
1 December 2007. Related: Conference reports, PK and drug interactions, Basic science and immunology.
BHIVA Autumn conference, 11-12 October 2007, London
29 October 2007. Related: Conference reports.
Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3
2 October 2007. Related: Conference reports.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney
3 September 2007. Related: Conference reports.
HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
3 September 2007. Related: Conference reports, Treatment strategies.
CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
3 September 2007. Related: Conference reports, Treatment strategies.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study
3 September 2007. Related: Conference reports, Paediatric care.
Very low transmission rates among breastfeeding women receiving ART
3 September 2007. Related: Conference reports, Pregnancy.
Use of pre-exposure prophylaxis (PrEP) by sero-different couples wanting to conceive a child
3 September 2007. Related: Conference reports, Pregnancy.
Increased incidence of miscarriage with efavirenz use
3 September 2007. Related: Conference reports, Pregnancy.
No impact of HSV-2 suppressive therapy on HIV incidence
3 September 2007. Related: Conference reports.
Penile washing directly after sex increased the risk of acquiring HIV: circumcision effective for men in high prevalence populations no protective effect in gay men
3 September 2007. Related: Conference reports.
HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis dont mix
3 September 2007. Related: Conference reports, Hepatitis coinfection.
9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney
3 September 2007. Related: Conference reports.
Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?
3 September 2007. Related: Conference reports.
Do children with perinatally acquired HIV infection have problems with metabolism and body shape?
3 September 2007. Related: Conference reports.
The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?
3 September 2007. Related: Conference reports.
Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?
3 September 2007. Related: Conference reports.
Can nucleoside RT inhibitors directly cause insulin resistance?
3 September 2007. Related: Conference reports.
Do dyslipidemia, insulin resistance, and body shape changes differ according to race or ethnicity?
3 September 2007. Related: Conference reports.
Is lipoatrophy associated with vascular dysfunction?
3 September 2007. Related: Conference reports.
XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados
7 July 2007. Related: Conference reports.
Integrase inhibitors and resistance
7 July 2007. Related: Conference reports, Drug resistance.
Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5
3 July 2007. Related: Conference reports, Drug resistance.
Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely
3 July 2007. Related: Conference reports, Drug resistance.
Higher risk of resistance using lopinavir/r monotherapy
3 July 2007. Related: Conference reports, Drug resistance.
Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen
3 July 2007. Related: Conference reports, Drug resistance.
Thirteen NNRTI mutations linked to resistance to etravirine (TMC-125)
3 July 2007. Related: Conference reports, Drug resistance.
14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles
3 July 2007. Related: Conference reports.
Protease inhibitors in pregnancy
3 July 2007. Related: Conference reports, Women's health.
Low rates of HCV treatment among eligible injection drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Effect of HCV and HIV on mortality among injecting drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
HCV/HIV-co-infected IDUs are at increased risk of death from hepatitis-related death in the HAART era, compared with HCV-mono-IDUs
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Long-term effectiveness of isoniazid prophylaxis on TB incidence in a cohort of IDUs
3 July 2007. Related: Conference reports, TB coinfection.
The dynamics of HCV transmission among injection drug users in St. Petersburg
3 July 2007. Related: Conference reports.
Founder effect among HIV-positive IDU in Karachi, Pakistan
3 July 2007. Related: Conference reports.
8th International Workshop on Clinical Pharmacology of HIV Therapy, April 2007, Budapest, Hungary
3 July 2007. Related: Conference reports.
Drug-drug interactions
3 July 2007. Related: Conference reports, PK and drug interactions.
Pharmacokinetic data with existing antiretrovirals
3 July 2007. Related: Conference reports.
Antiretroviral pharmacokinetics in special patient populations
3 July 2007. Related: Conference reports.
Pharmacology of investigational drugs
3 July 2007. Related: Conference reports.
14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles
5 May 2007. Related: Conference reports.
No benefit of early cessation of breastfeeding in the Zambia Exclusive Breastfeeding Study (ZEBS)
4 May 2007. Related: Conference reports, Pregnancy.
Role of infant feeding and HIV in a severe diarrhoea outbreak in Botswana
4 May 2007. Related: Conference reports, Pregnancy.
Diarrhoea in uninfected infants of HIV-positive mothers who stop breastfeeding at 6 Months
4 May 2007. Related: Conference reports, Pregnancy.
Post-weaning gastroenteritis and mortality in HIV-uninfected infants receiving antiretroviral prophylaxis
4 May 2007. Related: Conference reports, Pregnancy.
Rates of diarrhoea associated with early weaning among infants in the Kisumu breastfeeding study
4 May 2007. Related: Conference reports, Pregnancy.
Early breastfeeding cessation among infants and risk of serious gastroenteritis: findings from a perinatal prevention trial in Kampala, Uganda
4 May 2007. Related: Conference reports, Pregnancy.
Treating children in resource-limited settings
4 May 2007. Related: Conference reports, Paediatric care.